Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06260414 · 1 trial · 1 indication
Quantitative changes in ECG intervals
| Arm | Type | Description |
|---|---|---|
| SAD cohorts 1-7 Experimental Arm | EXPERIMENTAL | - |
| SAD Cohorts 1-7 Placebo Arm | PLACEBO_COMPARATOR | - |
| MAD cohorts 2-6 Experimental Arm | EXPERIMENTAL | - |
| MAD cohorts 2-6 Placebo Arm | PLACEBO_COMPARATOR | - |
| Japanese MAD cohort 7 Experimental arm | EXPERIMENTAL | - |
| Japanese MAD cohort 7 Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-06260414 | DRUG | Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format |
| Placebo | DRUG | Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format |
Inclusion Criteria: * Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory...
PF-06260414 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development, studied in healthy volunteers. The drug is not approved and remains under investigation for its safety and tolerability.
PF-06260414 is being studied for use in healthy volunteers, specifically to evaluate its safety and tolerability. It is an investigational small molecule in Phase 1 clinical development, with no approved indication at this time.
PF-06260414 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
PF-06260414 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in healthy volunteers to assess its safety and tolerability.
PF-06260414 has one completed Phase 1 trial, NCT02070939, which evaluated single and multiple ascending doses in healthy Western and Japanese male subjects. The trial enrolled 72 participants in the United States and was placebo-controlled and double-blind.
PF-06260414 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development, with one completed trial in healthy volunteers. It remains under study and has not been approved for any use.